On average, PD-L2 mutations are found in 0.83% of all cancers; the most common types are lung cancer, breast invasive ductal carcinoma, colon cancer, urothelial bladder carcinoma, and high-grade ovarian cancer [45]. Here, PDCD1LG2 is linked to bladder transitional cell carcinoma.